memantine   Click here for help

GtoPdb Ligand ID: 4253

Synonyms: Axura® | Ebixa® | Namenda®
Approved drug
memantine is an approved drug (EMA (2002), FDA (2003))
Compound class: Synthetic organic
Comment: Memantine is a non-competitive NMDA receptor antagonist approved for Alzheimer's disease but is also being studied in non-dementia psychiatric disorders [1] .
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: memantine

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 26.02
Molecular weight 179.17
XLogP 3.52
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC12CC3CC(C1)(C)CC(C2)(C3)N
Isomeric SMILES CC12CC3CC(C1)(C)CC(C2)(C3)N
InChI InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
No information available.
Summary of Clinical Use Click here for help
Memantine reduces clinical worsening in moderate to severe AD [2].
Memantine is a component of the approved AD fixed-dose medication Namzaric® (which contains memantine plus donepezil).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Memantine blocks NMDA glutamate channels. For a complete overview of the mechanism of action of memantine, please see the DrugBank link on the Summary tab of this ligand page..
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04302870 Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Phase 2/Phase 3 Interventional University of Edinburgh Memantine is one of the drugs being evaluated in the 'multi-arm' MND-SMART study as a therapeutic option for MND/ALS.
External links Click here for help